Pathologic staging of melanoma.

The American Joint Committee on Cancer (AJCC) recently launched a new staging system for cutaneous melanoma that was based on clinical experience with a large number of patients treated in major centers worldwide. As this system includes various histopathologic parameters of the primary melanoma and of melanoma metastasis, including micrometastases in the sentinel lymph node (SLN), they are discussed here. Special attention is given to ulceration of the primary tumor, because it remains a dominant prognostic parameter in addition to tumor thickness. Molecular markers that may reflect aggressive behavior of the primary melanoma also are described. Finally, pathologic examination of SLNs is addressed with emphasis on the efficacy of various microstaging approaches.

[1]  D. Ruiter,et al.  Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group , 2002, The Journal of pathology.

[2]  D. Elder,et al.  Melanoma-stroma interactions: structural and functional aspects. , 2002, The Lancet. Oncology.

[3]  J. J. van den Oord,et al.  Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. , 2001, The Journal of investigative dermatology.

[4]  A. Spatz,et al.  Microstaging in cutaneous melanoma , 2001, The Journal of pathology.

[5]  N. Cascinelli,et al.  Do patients with tumor-positive sentinel nodes constitute a homogeneous group? , 2001, Annals of surgical oncology.

[6]  A. Eggermont,et al.  The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer. , 2001, Annals of surgical oncology.

[7]  H. Olsson,et al.  Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review , 2001, Melanoma research.

[8]  N Cascinelli,et al.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Ross,et al.  Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. , 2001, Surgery.

[11]  P. V. van Diest,et al.  The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma , 2001, Cancer.

[12]  J. J. van den Oord,et al.  A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. , 2001, Cancer research.

[13]  Hong Wang,et al.  A micromorphometry‐based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma , 2001, Cancer.

[14]  K. Busam.  Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma. , 2001, American journal of clinical pathology.

[15]  Jonathan J. Lewis,et al.  Sentinel Lymph Node Biopsy in the Management of Patients With Primary Cutaneous Melanoma: Review of a Large Single-Institutional Experience With an Emphasis on Recurrence , 2001, Annals of surgery.

[16]  A. Eggermont,et al.  The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  S. Ugurel,et al.  Facts and pitfalls in the detection of tyrosinase mRNA in the blood of melanoma patients by RT-PCR. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[18]  D. Morton,et al.  The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. , 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[19]  M. McCarter,et al.  Role for Surgical Cytoreduction in Multimodality Treatments for Cancer , 2001, Annals of Surgical Oncology.

[20]  A. Hauschild,et al.  Sentinel node biopsy in melanoma , 2001, Virchows Archiv.

[21]  A. Paradiso,et al.  © 2000 Cancer Research Campaign , 2022 .

[22]  D. Majumdar,et al.  Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. , 2000, Cancer research.

[23]  D. Ruiter,et al.  Matrix metalloproteinases in human melanoma. , 2000, The Journal of investigative dermatology.

[24]  J. J. Coleman,et al.  Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma , 2000, Cancer.

[25]  J. Gibbs,et al.  Pathologic and Clinical Features Influencing Outcome of Thin Cutaneous Melanoma: Correlation with Newly Proposed Staging System , 2000, The American surgeon.

[26]  R. Elashoff,et al.  Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. , 2000, Cancer research.

[27]  C. Garbe,et al.  Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. , 2000, The Journal of investigative dermatology.

[28]  Martin F. Mihm,et al.  A new American Joint Committee on Cancer staging system for cutaneous melanoma , 2000, Cancer.

[29]  M. Mihm,et al.  Long-Term Results of a Multi-Institutional Randomized Trial Comparing Prognostic Factors and Surgical Results for Intermediate Thickness Melanomas (1.0 to 4.0 mm) , 2000, Annals of Surgical Oncology.

[30]  A. Marghoob,et al.  Breslow thickness and Clark level in melanoma , 2000, Cancer.

[31]  I. B. Rinkes,et al.  Sentinel Node Biopsies in Melanoma Patients: A Protocol for Accurate, Efficient, and Cost-Effective Analysis by Preselection for Immunohistochemistry on the Basis of Tyr-PCR , 2000, Annals of Surgical Oncology.

[32]  A. Cochran.  Surgical pathology remains pivotal in the evaluation of 'sentinel' lymph nodes. , 1999, The American journal of surgical pathology.

[33]  R. Elashoff,et al.  Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Lippold,et al.  Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? , 1999, Cancer.

[35]  D. Reintgen,et al.  Pathologic examination of the sentinel lymph node in malignant melanoma. , 1999, The American journal of surgical pathology.

[36]  D. Elder,et al.  Progression-related expression of beta3 integrin in melanomas and nevi. , 1999, Human pathology.

[37]  T. Goldmann,et al.  Prognostic Classification of Malignant Melanomas by Combining Clinical, Histological, and Immunohistochemical Parameters , 1999, Oncology.

[38]  D. Coit,et al.  Detection of Tyrosinase mRNA by Reverse Transcription Polymerase Chain Reaction in Melanoma Sentinel Nodes , 1999, Annals of Surgical Oncology.

[39]  M. Ross,et al.  Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Coit,et al.  Prognosis of thick cutaneous melanoma. , 1999, Journal of the American College of Surgeons.

[41]  K. Alitalo,et al.  Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression. , 1999, Melanoma research.

[42]  A. Shilkaitis,et al.  Molecular prognostic markers in intermediate‐thickness cutaneous malignant melanoma , 1999, Cancer.

[43]  D. Krag,et al.  Sentinel lymph node biopsy for melanoma. , 1998, American journal of surgery.

[44]  J. Thompson,et al.  Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (> 5 mm) , 1998, Histopathology.

[45]  G. Lyman,et al.  Molecular staging of malignant melanoma: correlation with clinical outcome. , 1998, JAMA.

[46]  E. Mansour,et al.  A long-term analysis of 620 patients with malignant melanoma at a major referral center. , 1998, Surgery.

[47]  M. Kallioinen,et al.  Prognostic value of MMP‐2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma , 1998, The Journal of pathology.

[48]  S. Leong,et al.  Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. , 1998, Archives of dermatology.

[49]  V. Kosma,et al.  Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma. , 1998, British Journal of Cancer.

[50]  N. Swanson,et al.  Clinical and histologic trends of melanoma. , 1998, Journal of the American Academy of Dermatology.

[51]  G. Wilson,et al.  Expression of c‐myc oncoprotein represents a new prognostic marker in cutaneous melanoma , 1998, The British journal of surgery.

[52]  D. Coit,et al.  The detection of micrometastases in melanoma sentinel nodes by step-sectioning and immunohistochemical staining: 435 , 1997 .

[53]  H. Olsson,et al.  Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985 , 1997, Cancer.

[54]  A. Maes,et al.  CD40 is a prognostic marker in primary cutaneous malignant melanoma. , 1996, The American journal of pathology.

[55]  M. Mihm,et al.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. , 1996, Annals of surgery.

[56]  M. Berwick,et al.  Predicting five‐year outcome for patients with cutaneous melanoma in a population‐based study , 1996, Cancer.

[57]  A. Ganser,et al.  Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. , 1996, Journal of the National Cancer Institute.

[58]  R. Corona,et al.  Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M. Gore,et al.  Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  G. Lyman,et al.  The tumor biology of melanoma nodal metastases. , 1996, The American surgeon.

[61]  A. Schauer,et al.  Antigen Ki-67 and c-myc oncogene as related to histoclinical parameters in pigmented skin lesions. , 1995, In vivo.

[62]  L. Xerri,et al.  Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. , 1995, Archives of dermatology.

[63]  R. MacKie,et al.  Prognostic models for subgroups of melanoma patients from the Scottish Melanoma Group database 1979-86, and their subsequent validation. , 1995, British Journal of Cancer.

[64]  P. Andersen,et al.  Observer variation in histological classification of cutaneous malignant melanoma. , 1995, Scandinavian journal of plastic and reconstructive surgery and hand surgery.

[65]  H. Adami,et al.  Trends in tumour characteristics and survival of malignant melanoma 1960-84: a population-based study in Sweden. , 1994, British Journal of Cancer.

[66]  Meir Shinitzky,et al.  Structural and functional aspects , 1994 .

[67]  I. Shih,et al.  Autocrine and paracrine roles for growth factors in melanoma. , 1994, In vivo.

[68]  C. Balch,et al.  Cutaneous melanoma: prognosis and treatment results worldwide. , 1992, Seminars in surgical oncology.

[69]  H. Frydman,et al.  Malignant melanoma. Changing trends in factors influencing metastasis‐free survival from 1964 to 1982 , 1990, Cancer.

[70]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[71]  R. Vollmer.  Malignant melanoma. A multivariate analysis of prognostic factors. , 1989, Pathology annual.

[72]  A. Cochran,et al.  Occult Tumor Cells in the Lymph Nodes of Patients with Pathological Stage I Malignant Melanoma An Immunohistological Study , 1988, The American journal of surgical pathology.

[73]  N. Cascinelli,et al.  Prognostic factors for stage I melanoma of the skin: a review. , 1985, Statistics in medicine.

[74]  C. Balch,et al.  The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma , 1985, Cancer.

[75]  C. Balch,et al.  PROGNOSTIC HISTOPATHOLOGICAL FACTORS IN MALIGNANT MELANOMA , 1985, Pathology.

[76]  C. Holman,et al.  Inter‐observer variation between pathologists in the classification of cutaneous malignant melanoma in Western Australia , 1984, Histopathology.

[77]  C. Balch,et al.  A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  C. Balch,et al.  A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, Australia , 1982, Annals of surgery.

[79]  V. McGovern,et al.  Ulceration and prognosis in cutaneous malignant melanoma , 1982, Histopathology.

[80]  C. Balch,et al.  The prognostic significance of ulceration of cutaneous melanoma , 1980, Cancer.

[81]  C. Balch,et al.  A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. , 1979, Surgery.

[82]  H. Johnson.  ABDOMINAL PAIN OF SPINAL ORIGIN , 1965, The Lancet.

[83]  A. Cochran,et al.  Assessment of prognosis in patients with malignant melanoma. , 1972, Lancet.

[84]  V. Tompkins.  Cutaneous melanoma: Ulceration as a prognostic sign , 1953, Cancer.

[85]  A. Allen,et al.  Malignant melanoma. A clinicopathological analysis of the criteria for diagnosis and prognosis , 1953, Cancer.